{"title": "PDF", "author": "PDF", "url": "https://www.onkopedia.com/de/wissensdatenbank/wissensdatenbank/mammakarzinom/v430-janni-100-vortrag.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "PI3K andbeyond\n1.10.2017 \nWolfgang Janni\nUniversit\u00e4tsfrauenklinik, Universit\u00e4t Ulm\nDisclosures\nResearch Grants and/or honoraria  from:\nSanofi -Aventis, Novartis, Roche, Pfizer, AstraZeneca, Chugai, \nGSK, Eisai, Cellgene, Johnson&JohnsonPI3K andbeyond\n-Landscape endokrine Therapie \nmetastasierter Brustkrebs\n-PI3K -Inhitoren \u2013aktuelle Datenlage\n-PARP -Inhibition\n-Ausblick\nPI3K andbeyond\n-Landscape endokrine Therapie \nmetastasierter Brustkrebs\n-PI3K -Inhitoren \u2013aktuelle Datenlage\n-PARP -Inhibition\n-Ausblick\nIn der Therapieentscheidung die richtige Balance finden\nDie Lebensqualit\u00e4t muss \nim Vordergrund stehen, \nund somit die \nVertr\u00e4glichkeit der \nTherapie\nEffektivit\u00e4t NebenwirkungenDie Behandlung von \nmetastasiertem\nBrustkrebs kann die \nErkrankung\nstabilisieren , aber nicht\nheilen\nFaktoren, die die Therapieentscheidung bei Auftreten \nvon Fernmetastasen beeinflussen\nAlter, PS, \nBegleiterkrankungen\nKrankheits -Charakteristika\n Patientenprofil\nSozio -\u00f6konomische und \npsychologische Faktoren\n(z.B. Entfernung zum\nKrankenhaus ; Kosten )\nMenopausenstatus\nPatientenpr\u00e4ferenz\n(z.B. oral vs i.v.\nBehandlung )\nAgressivit\u00e4t der Erkrankung\nLeidensdruck\nVortherapien und \nTherapieansprechen\nER/PgR, HER2 Rezeptor\nStatus\nKrankheitsfreies\nIntervall\nVorausgehende adjuvante\nTherapie\nLeitlinien , Zugang und \nTherapiekosten\nFaktoren, die die Therapieentscheidung bei Auftreten \nvon Fernmetastasen beeinflussen\nAlter, PS, \nBegleiterkrankungen\nKrankheits -Charakteristika\n Patientenprofil\nSozio -\u00f6konomische und \npsychologische Faktoren\n(z.B. Entfernung zum\nKrankenhaus ; Kosten )\nMenopausenstatus\nPatientenpr\u00e4ferenz\n(z.B. oral vs i.v.\nBehandlung )\nAgressivit\u00e4t der Erkrankung\nLeidensdruck\nVortherapien und \nTherapieansprechen\nER/PgR, HER2 Rezeptor\nStatus\nKrankheitsfreies\nIntervall\nVorausgehende adjuvante\nTherapie\nLeitlinien , Zugang und \nTherapiekosten\n1896: Ovarektomie\n(Beatson)\n1922: Radiomenolyse\n1940: \u00d6strogene\n1951: Adrenalektomie\n1960: Androgene\n1971: Tamoxifen\n1985: GnRH -Analoga\n1998: Aromatase -Hemmer\n2000: \u00d6strogenrezeptor -\nDownregulator\nSeit 2010: \nKombinationstherapienGene transcriptionGrowth factor \nreceptor\nEstradiol\nmTOR \ninhibitorsEstrogen receptor \ndown -regulatorPI3K inhibitors\nEstrogen receptor \nmodulatorAromatase \ninhibitors\nPI3K\nAKT\n ER\nGRB2\nP\nP\nP\n P\nER\nCoA\nER\nCoA\nAP1\nP\nCoA\nTFs\nEREs\n AP1/SP1\n TFs\n-\nREs\nP\nER\nS6KI\nSOS\nShc\nRb\nE2F\n E2F\nCyclin D\nCDK4/6\nP\nP\nP\nP\n P\nCyclin D\nCDK4/6CDK4/6 inhibitors\nP\n P\nmTOR\nRas\nRaf\nMEK\nMAPK\n Established \nTargetsInnovative \nTherapeutic TargetsWeiterentwicklung der endokrinen Therapie \u2013\nintrazellul\u00e4re SignalwegeGene transcriptionGrowth factor \nreceptor\nEstradiol\nmTOR \ninhibitorsEstrogen receptor \ndown -regulatorPI3K inhibitors\nEstrogen receptor \nmodulatorAromatase \ninhibitors\nPI3K\nAKT\n ER\nGRB2\nP\nP\nP\n P\nER\nCoA\nER\nCoA\nAP1\nP\nCoA\nTFs\nEREs\n AP1/SP1\n TFs\n-\nREs\nP\nER\nS6KI\nSOS\nShc\nRb\nE2F\n E2F\nCyclin D\nCDK4/6\nP\nP\nP\nP\n P\nCyclin D\nCDK4/6CDK4/6 inhibitors\nP\n P\nmTOR\nRas\nRaf\nMEK\nMAPK\n Established \nTargetsInnovative \nTherapeutic TargetsWeiterentwicklung der endokrinen Therapie \u2013\nintrazellul\u00e4re SignalwegePI3K andbeyond\n-Landscape endokrine Therapie \nmetastasierter Brustkrebs\n-PI3K -Inhitoren \u2013aktuelle Datenlage\n-PARP -Inhibition\n-Ausblick\nPI3K -Phosphoinositid -3-Kinasen\n\u2022Heterodimere aus regulatorischer (p85 \u03b1) und katalytischer (p110 \u03b1) \nUntereinheit; p110 \u03b1kodiert durch PIK3CA\n\u2022Involviert in Zellwachstum, Zellproliferation, Migration, \nDifferenzierung, \u00dcberleben und Zelladh\u00e4sion\nPIK3CA -Mutationen sehr h\u00e4ufig in MammaCa (20-40%) \n(Isakoff et al. 2005)\nBaselga 2011, The Oncologist\nCourtesy T. FehmPI3K/ mTOR und CDK4/6 Pathways\nPI3K\nRTK\nER\nEstrogen\nPIP2\nPIP3\nPTEN\nAKT\nmTORC1\nmTORC2\nCyclin D\nCDK4/6RTKs can be \noverexpressed \nor overactivated\nin cancer\nPTEN (tumor suppressor) \nmutation or loss of expression \n(13%) are also detected in \nluminal A BC1PIK3CA mutation is the \nmost frequent genetic \nalteration (45 \u201349% of \nluminal A BC)1\nCyclin D1 amplification (29\u201358%)\nCDK4 amplification (14\u201325%),\nCDK6 amplification (17%), and loss of \np16(49%) are detected in BC1,2\nBC, breast cancer; CDK, cyclin dependent kinase; ER, estrogen receptor; mTOR , mammalian target of rapomycin ; PIK3CA, phosphatidylinositol -4,5-bisphosphate 3 -kinase \nPIP2, phosphatidylinositol 4,5 -biphosphate; PIP3, phosphatidylinositol 3,4,5 -trisphosphate; PI3K, phosphoinositide 3 -kinase; PTEN, phosphatase and tensin homolog; \nRTK, receptor tyrosine kinase.\n1. The Cancer Genome Atlas Network. Nature. 2012; 490:61 \u201370; 2. Geradts J, Wilson PA, Am J Pathol .1996:149:15 \u201320.PI3K Inhibitoren in Phase III Testung\nIC50, half maximal inhibitory concentration; Ki, inhibitor constant.\n1. Maira SM et al. MolCancer Ther. 2012;11:317 \u201328; 2. Folkes AJ et al. J Med Chem 2008;51:5522 \u20135532; \n3. Fritsch CM et al. Cancer Res. 2012;72: Abstract 3748 ; 4. Olivero et al. AACR 213; Abstract DDT02 -01.\nBuparlisib\n Alpelisib\n Taselisib\nPan-Class I\nPI3K inhibitor1Isoform -specific \nPI3K inhibitor3Isoform -specific \nPI3K inhibitor4\n\u03b1\n \u03b2\n \u03b3\n \u03b4\n \u03b1\nIC50\n(nM)52 166 262 116 IC505 nM\n\u03b1\nKi0.2 nM\nPictilisib\nPan-Class I\nPI3K inhibitor2\n\u03b1\n \u03b2\n \u03b3\n \u03b4\n3 33 3 75Vier PI3K -Inhibitoren derzeit in Phase III TestungPI3K Inhibitoren in Phase III Testung\nIC50, half maximal inhibitory concentration; Ki, inhibitor constant.\n1. Maira SM et al. MolCancer Ther. 2012;11:317 \u201328; 2. Folkes AJ et al. J Med Chem 2008;51:5522 \u20135532; \n3. Fritsch CM et al. Cancer Res. 2012;72: Abstract 3748 ; 4. Olivero et al. AACR 213; Abstract DDT02 -01.\nBuparlisib\nPan-Class I\nPI3K inhibitor1\n\u03b1\n \u03b2\n \u03b3\n \u03b4\nIC50\n(nM)52 166 262 116\nPictilisib\nPan-Class I\nPI3K inhibitor2\n\u03b1\n \u03b2\n \u03b3\n \u03b4\n3 33 3 75Vier PI3K -Inhibitoren derzeit in Phase III TestungPI3K Inhibitoren in Phase III Testung\nIC50, half maximal inhibitory concentration; Ki, inhibitor constant.\n1. Maira SM et al. MolCancer Ther. 2012;11:317 \u201328; 2. Folkes AJ et al. J Med Chem 2008;51:5522 \u20135532; \n3. Fritsch CM et al. Cancer Res. 2012;72: Abstract 3748 ; 4. Olivero et al. AACR 213; Abstract DDT02 -01.IC50\n(nM)52 166 262 116\nPictilisib\nPan-Class I\nPI3K inhibitor2\n\u03b1\n \u03b2\n \u03b3\n \u03b4\n3 33 3 75Vier PI3K -Inhibitoren derzeit in Phase III TestungFazit Pictilisib -Kombinationstherapien\n\u2022Nebenwirkungen mit Pictilisib typisch f\u00fcr \nPan-PI3K -Inhibitoren\n\u2022Met. Brustkrebs:\n\u2022Numerischer PFS-Zugewinn, aber \nmoderat und nicht signifikant\n\u2022PI3K -Mutation nicht pr\u00e4diktiv\n\u2022Neo-Adjuvant :\n\u2022Signifikant h\u00f6herer und \neindrucksvoller Abfall von Ki67 mit \nPictilisib , aber keine \n\u00dcberlebensdaten\n\u2022PI3K -Mutation nicht pr\u00e4diktiv\nPI3K Inhibitoren in Phase III Testung\nIC50, half maximal inhibitory concentration; Ki, inhibitor constant.\n1. Maira SM et al. MolCancer Ther. 2012;11:317 \u201328; 2. Folkes AJ et al. J Med Chem 2008;51:5522 \u20135532; \n3. Fritsch CM et al. Cancer Res. 2012;72: Abstract 3748 ; 4. Olivero et al. AACR 213; Abstract DDT02 -01.\nBuparlisib\nPan-Class I\nPI3K inhibitor1\n\u03b1\n \u03b2\n \u03b3\n \u03b4\nIC50\n(nM)52 166 262 116 3 33 3 75Vier PI3K -Inhibitoren derzeit in Phase III TestungThis presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nPIK3CA Status in Circulating Tumor DNA Predicts Efficacy of \nBuparlisib Plus Fulvestrant in Postmenopausal Women With \nEndocrine -resistant HR+/HER2 \u2013Advanced Breast Cancer: \nFirst Results From the Randomized, Phase III BELLE -2 Trial\nJos\u00e9 Baselga,1Seock -Ah Im,2 Hiroji Iwata,3 Mark Clemons,4 Yoshinori Ito,5 Ahmad Awada,6 Stephen Chia,7 \nAgnieszka Jagie\u0142\u0142o -Gruszfeld,8 Barbara Pistilli,9 Ling -Ming Tseng,10 Sara Hurvitz,11 Norikazu Masuda,12 Javier Cort\u00e9s,13 \nMichele De Laurentiis,14 Carlos L. Arteaga,15 Zefei Jiang,16 Walter Jonat,17 Soulef Hachemi,18 Sylvie Le Mouha\u00ebr,18 \nEmmanuelle Di Tomaso,19 Patrick Urban,20 Cristian Massacesi,18 Mario Campone21 \n1Memorial Sloan Kettering Cancer Center, New York, NY\u037e 2Seoul National University College of Medicine, Seoul, Republic of Korea; \n3Aichi Cancer Center, Nagoya, Japan; 4Ottawa Hospital Research Institute, Ottawa, Canada; \n5Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan; 6Institut Jules Bordet, Brussels, Belgium; \n7BC Cancer Agency, Vancouver, Canada; 8Maria Sk\u0142odowska -Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, Poland; \n9Ospedale di Macerata, Macerata, Italy; 10Taipei Veterans General Hospital, Taipei, Taiwan; 11UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA; \n12National Hospital Organization Osaka National Hospital, Osaka, Japan; 13Vall d\u2019Hebron Institute of Oncology (VHIO), Barcelona, Spain\u037e \n14Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy; 15Vanderbilt -Ingram Cancer Center, Nashville, TN; 16Beijing 307 Hospital of PLA, Beijing, China; \n17University Hospital Schleswig -Holstein, Kiel, Germany; 18Novartis Pharma S.A.S., Paris, France; 19Novartis Institutes for BioMedical Research, Cambridge, MA; \n20Novartis Pharma AG, Basel, Switzerland; 21Institut de Canc\u00e9rologie de l\u2019Ouest \u2013Ren\u00e9 Gauducheau Centre de Recherche en Canc\u00e9rologie, Nantes, France\n34This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nBELLE -2 Study Design and Endpoints\n35BELLE -2: ClinicalTrials.gov NCT01610284. \nAI, aromatase inhibitor; BEAMing , beads, emulsification, amplification, and magnetics; ctDNA, circulating tumor DNA; HER2 \u2013, human epidermal growth factor recept or 2 negative; \nHR+, hormone receptor -positive; PFS, progression -free survival; PI3K, phosphatidylinositol 3 -kinase.\n*PI3K pathway activation (activated, non -activated, unknown) was assessed in archival tumor tissue provided at screening, define d as PIK3CA mutation by Sanger sequencing (any \nmutations in exons 1, 7, 9, or 20) and/or loss of PTEN expression by immunohistochemistry (1+ expression in <10% of cells); \u2020 ctDNA PIK3CA status was assessed by BEAMing technology.\nPrimary Endpoints\n\u2022PFS in the main population (PI3K activated \nand non -activated, excluding status unknown*)\n\u2022PFS in the PI3K activated group* \n(PIK3CA mutation and/or PTEN loss in \narchival tissue)\n\u2022PFS in the full population (local assessment)\nKey Secondary Endpoint\n\u2022Overall survival\nOther Secondary Endpoints\n\u2022Overall response rate\n\u2022Clinical benefit rate\n\u2022Safety, pharmacokinetics, quality of life\nExploratory Endpoint\n\u2022PFS by ctDNA PIK3CA mutation status\u2020Randomization (1:1)\nStratification by PI3K pathway* and visceral disease statusPostmenopausal women with HR+/HER2 \u2013locally advanced or \nmetastatic breast cancer that progressed on/after AI therapy\nN=1147\nBuparlisib (100 mg/day) \n+ fulvestrant (500 mg)\nn=576Placebo\n+ fulvestrant (500 mg)\nn=571This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nBELLE -2 Safety Profile Was Characterized by Hyperglycemia, \nTransaminitis, Rash, and Mood Disorders\n\u2022 Serious adverse events occurred in 23.4% of patients in the buparlisib arm vs 15.8% in the placebo arm\n\u2022 12 on -treatment deaths (2.1%) were reported in each arm in the full population, the majority due to disease progression\n36ALT, alanine aminotransferase; AST, aspartate aminotransferase .Buparlisib + Fulvestrant\nn=573Placebo + Fulvestrant\nn=570\nAdverse event, % All grades Grade 3 Grade 4 All grades Grade 3 Grade 4\nTotal 99.5 63.2 14.1 93.0 27.4 4.6\nIncreased ALT 40.1 18.7 6.8 6.8 1.1 0\nIncreased AST 37.3 15.0 3.0 9.3 2.8 0\nHyperglycemia 43.1 15.2 0.2 7.7 0.2 0\nRash 32.1 7.7 0.2 6.3 0 0\nAnxiety 22.3 5.2 0.2 8.2 0.9 0\nFatigue 31.9 4.9 0 23.9 1.6 0\nDepression 26.2 3.7 0.7 8.9 0.4 0\nDiarrhea 34.2 3.7 0 14.6 1.1 0\nAsthenia 20.1 2.8 0 10.5 1.1 0\nStomatitis 21.6 2.1 0 6.5 0.5 0\nNausea 38.7 1.7 0 23.2 1.4 0\nDecreased appetite 29.8 1.6 0 11.1 0.2 0This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nBELLE -2 Met the Primary Endpoint for Statistically Significant \nPFS Improvement in the Full and Main Population\n\u2022 A similar PFS improvement was observed in the main population (HR 0.80 [95% CI: 0.68 \u20130.94]; one -sided P value 0.003)\n\u2022 Follow -up for OS analysis is ongoing, with a pre -specified target of 588 deaths in the full population\n\u2013 At the time of primary PFS analysis, OS data were immature (281 deaths in the full population), with a trend in favor of the buparlisib arm\n37CI, confidence interval; HR, hazard ratio; OS, overall survival; PFS, progression -free survival.Full Population \n(N=1047)Buparlisib + \nFulvestrant\nn=576Placebo + \nFulvestrant\nn=571\nMedian PFS, \nmonths (95% CI)6.9\n(6.8\u20137.8)5.0\n(4.0\u20135.2)\nHR (95% CI) 0.78 (0.67 \u20130.89)\nOne-sided\nPvalue<0.001Probability of \nProgression -free Survival, %\nTime (Months)100\n60\n080\n40\n20\n0 4 8 14 18 2 6 10 12 16 20 26 30 22 24 28Buparlisib + fulvestrant (n/N=349/576)\nPlacebo + fulvestrant (n/N=435/571)This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nPFS Increase in the PI3K Activated Group Was \nNot Statistically Significant\n38*PFS in the PI3K activated group was tested at a one -sided \u03b1=0.01 level of significance.\nCI, confidence interval; HR, hazard ratio; PFS, progression -free survival; PI3K, phosphatidylinositol 3 -kinase .PI3K Activated \nGroup (N=372)Buparlisib + \nFulvestrant\nn=188Placebo + \nFulvestrant\nn=184\nMedian PFS, \nmonths (95% CI)6.8\n(4.9\u20137.1)4.0\n(3.1\u20135.2)\nHR (95% CI) 0.76 (0.60 \u20130.97)\nOne-sided\nPvalue*0.014\nTime (Months)Probability of \nProgression -free Survival, %100\n60\n080\n40\n20\n0 4 8 14 18 2 6 10 12 16 20 26 30 22 24 28Buparlisib + fulvestrant (n/N=116/188)\nPlacebo + fulvestrant (n/N=144/184)This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nBuparlisib and Fulvestrant Produced a Clinically Meaningful \nPFS Improvement in Patients With ctDNA PIK3CA Mutations\n39CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; PFS, progression -free survival. ctDNA PIK3CA Mutant\nn=200Buparlisib + \nFulvestrant\nn=87Placebo + \nFulvestrant\nn=113\nMedian PFS, months \n(95% CI)7.0 \n(5.0\u201310.0)3.2 \n(2.0\u20135.1)\nHR (95% CI) 0.56 (0.39 \u20130.80)\nOne-sided nominal Pvalue <0.001Probability of \nProgression -free Survival, %\nTime (Months)100\n60\n080\n40\n20\n0 4 8 14 18 2 6 10 12 16 20 22Buparlisib + fulvestrant (n/N=48/87)\nPlacebo + fulvestrant (n/N=90/113)This presentation is the intellectual property of the author/presenter. Contact them at baselgaj@mskcc.org for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 8 \u201312, 2015\nBuparlisib and Fulvestrant Produced a Clinically Meaningful \nPFS Improvement in Patients With ctDNA PIK3CA Mutations\n40CI, confidence interval; ctDNA, circulating tumor DNA; HR, hazard ratio; PFS, progression -free survival. ctDNA PIK3CA Mutant\nn=200Buparlisib + \nFulvestrant\nn=87Placebo + \nFulvestrant\nn=113\nMedian PFS, months \n(95% CI)7.0 \n(5.0\u201310.0)3.2 \n(2.0\u20135.1)\nHR (95% CI) 0.56 (0.39 \u20130.80)\nOne-sided nominal Pvalue <0.001ctDNA PIK3CA\nNon-mutant\nn=387Buparlisib + \nFulvestrant\nn=199Placebo + \nFulvestrant\nn=188\nMedian PFS, months \n(95% CI)6.8 \n(4.7\u20138.5)6.8 \n(4.7\u20138.6)\nHR (95% CI) 1.05 (0.82 \u20131.34)\nOne-sided nominal Pvalue 0.642Probability of \nProgression -free Survival, %\nTime (Months)100\n60\n080\n40\n20\n0 4 8 14 18 2 6 10 12 16 20 26 28 22 24Buparlisib + fulvestrant (n/N=124/199)\nPlacebo + fulvestrant (n/N=126/188)Probability of \nProgression -free Survival, %\nTime (Months)100\n60\n080\n40\n20\n0 4 8 14 18 2 6 10 12 16 20 22Buparlisib + fulvestrant (n/N=48/87)\nPlacebo + fulvestrant (n/N=90/113)This presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n41BELLE -3: A Phase III Study of Buparlisib and Fulvestrant\nin Postmenopausal Women With HR+, HER2 \u2013, AI-treated, \nLocally Advanced or Metastatic Breast Cancer, Who \nProgressed On or After mTOR Inhibitor -based Treatment\nAngelo Di Leo,1Keun Seok Lee,2Eva Ciruelos,3Per L\u00f8nning,4Wolfgang Janni,5Ruth O\u2019Regan,6\nMarie -Ange Mouret Reynier,7Dimitar Kalev,8Daniel Egle,9Tibor Cs\u0151szi,10Roberto Bordonaro,11\nThomas Decker,12Vivianne CG Tjan -Heijnen,13Sibel Blau,14Alessio Schirone,15Denis Weber,16\nMona El -Hashimy,17Bharani Dharan,17Dalila Sellami,17Thomas Bachelot18 \n1Ospedale Misericordia e Dolce, Prato, Italy; 2National Cancer Center, Gyeonggi -do, Republic of Korea; 3Hospital Universitario 12 de Octubre, Madrid, Spain; \n4Haukeland University Hospital, Bergen, Norway; 5Universit\u00e4tsklinikum Ulm, Ulm, Germany; 6University of Wisconsin -Madison, Madison, WI; \n7Centre Jean Perrin, Clermont -Ferrand, France; 8Medical University of Varna, Varna, Bulgaria; 9Medizinische Universit\u00e4t Innsbruck , Innsbruck, Austria; \n10JNSZ Megyei Het\u00e9nyi G\u00e9za K\u00f3rh\u00e1z -Rendel\u0151int\u00e9zet, Szolnok, Hungary\u037e 11ARNAS Garibaldi, Catania, Italy; \n12Onkonet \u2013Onkologie Ravensburg, Ravensburg, Germany; 13Maastricht University Medical Center+, Maastricht, The Netherlands; \n14Rainier Hematology -Oncology/Northwest Medical Specialties, Tacoma, WA; \n15Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), Meldola, Italy; \n16Novartis Pharma AG, Basel, Switzerland; 17Novartis Pharmaceuticals Corporation, East Hanover, NJ; 18Centre L\u00e9on B\u00e9rard, Lyon, FranceThis presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n42\u2022Tumor assessments were performed every 6 weeks\n\u202290% power to detect a 33% risk reduction in PFS (disease progression or death) \nat one -sided \u03b1=0.025 , based on the observation of 313 PFS eventsBELLE -3 Study Design and Endpoints\nRandomization (2:1)\nStratified by visceral \ndisease statusBuparlisib (100 mg/day) \n+ fulvestrant (500 mg)\nn=289 \nPlacebo\n+ fulvestrant (500 mg)\nn=143Primary endpoint\n\u2022PFS (locally assessed per \nRECIST v1.1)\nKey secondary endpoint\n\u2022OS\nOther secondary endpoints\n\u2022PFS by PIK3CA status (ctDNA)\n\u2022OS by PIK3CA status (ctDNA)\n\u2022ORR and CBR in the full \npopulation and by PIK3CA\nstatus (ctDNA)\n\u2022Safety, pharmacokinetics, \nquality of life\u2022Postmenopausal women with \nHR+/HER2 \u2013, AI-pretreated, \nlocally advanced or \nmetastatic breast cancer \n\u2022Progression on or after \nan mTOR inhibitor as \nlast line \nof treatment\n\u2022N=432\nAI, aromatase inhibitor; CBR, clinical benefit rate; ctDNA, circulating tumor DNA; HER2 \u2013, human epidermal growth factor receptor 2-negative; HR+, hormone receptor -positive; \nmTOR, mammalian target of rapamycin; ORR, overall response rate; OS, overall survival; PFS, progression -free survival; RECIST, R esponse Evaluation Criteria In Solid Tumors.\nBELLE -3: ClinicalTrials.gov NCT01633060. This presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n43CharacteristicBuparlisib + \nFulvestrant (n=289)Placebo + \nFulvestrant (n=143)All Patients\n(N=432)\nMedian age, years (range) 60 (32 \u201384) 62 (37 \u201379) 61 (32 \u201384)\n\u22653 metastatic sites, % 64 67 65\nVisceral metastases, % 73 72 73\nPrior chemotherapy for \nmetastatic disease, %36 34 35\n\u22652 lines of endocrine therapy for \nmetastatic disease, %\n(Prior fulvestrant was not permitted)70 66 69Key Patient and Tumor Characteristics This presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n44\u2022PFS results by independent central review were consistent with local assessment:\n\u2013HR 0.57 (95% CI: 0.44 \u20130.74; one -sided p<0.001)Progression -free Survival per Investigator Assessment \n(Primary Endpoint)\nCI, confidence interval; HR, hazard ratio.6-month PFS rate:\n31% vs. 20%100\n80\n60\n40\n20\n0\n0 4 8 2 6 10 12 14 16 18 20 22 24 26\nTime, MonthsProbability of \nProgression -free Survival, %Full Population \n(N=432)Buparlisib + \nFulvestrant\nn=289Placebo + \nFulvestrant\nn=143\nMedian PFS, \nmonths (95% CI)3.9 \n(2.8\u20134.2)1.8\n(1.5\u20132.8)\nHR (95% CI) 0.67 (0.53 \u20130.84)\nOne-sided p-value <0.001This presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n45Subgroup Analyses of PFS\nECOG, Eastern Cooperative Oncology Group; ER+, estrogen receptor -positive; PgR\u2013, progesterone receptor -negative; PgR+, progesterone receptor -positive.Hazard ratio for PFS (95% CI)\n<65years (n=274) 0.69 (0.51 \u20130.92)\n\u226565 years (n=158) 0.63 (0.42 \u20130.93)\n0(n=264) 0.58 (0.43 \u20130.78)\n1 or 2 (n=163) 0.80 (0.54 \u20131.18)\n(Neo)adjuvant setting only (n=189) 0.67 (0.47 \u20130.96)\nMetastatic setting (n=152) 0.74 (0.50 \u20131.11)\nNone (n=91) 0.59 (0.36 \u20130.96)\n1(n=103) 0.53 (0.33 \u20130.87)\n2(n=219) 0.72 (0.52 \u20130.99)\n\u22653(n=110) 0.73 (0.46 \u20131.16)\nER+, PgR+ (n=343) 0.66 (0.50 \u20130.85)\nER+, PgR \u2013(n=85) 0.70 (0.42 \u20131.18)\nClinical benefit (n=284) 0.75 (0.57 \u20131.00)\nNo clinical benefit (n=148) 0.47 (0.32 \u20130.71)\nFavors Buparlisib + Fulvestrant Favors Placebo + Fulvestrant0.25 0.5 0.75 1 1.5 2Age\nECOG performance status\nPrior \nchemotherapy\nHormone receptor status\nSensitivity to last \nendocrine therapy + \nmTOR inhibitorPrior lines of therapyThis presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n46Progression -free Survival by PIK3CA Status\n100\n80\n60\n40\n20\n0\n20181614121086420 262422100\n80\n60\n40\n20\n0\n20 18 16 14 12 10 8 6 4 2 0Probability of PFS, %Tissue (mutant)Buparlisib + \nFulvestrantPlacebo + \nFulvestrant\nMedian PFS, \nmonths (95% CI)4.7\n(2.9\u20136.7)1.4\n(1.4\u20132.2)\nHR (95% CI) 0.39 (0.23 \u20130.65); p<0.001\nPCR, polymerase chain reaction; WT, wild -type.\np-values are one -sided.100\n80\n60\n40\n20\n0\n26 20 18 16 14 12 108 6 4 2 0 24 22Probability of PFS, %100\n80\n60\n40\n20\n0\n20181614121086420 262422Primary tumor \ntissue (PCR) \nN=321\nPIK3CA mutant: \n34%\nTime, Months Time, MonthsTissue (WT)Buparlisib + \nFulvestrantPlacebo + \nFulvestrant\nMedian PFS, \nmonths (95% CI)2.8\n(2.0\u20133.7)2.7\n(1.4\u20132.9)\nHR (95% CI) 0.83 (0.60 \u20131.14); p=0.117\nctDNA (WT)Buparlisib + \nFulvestrantPlacebo + \nFulvestrant\nMedian PFS, \nmonths (95% CI)3.9\n(2.8\u20134.3)2.7\n(1.5\u20133.6)\nHR (95% CI) 0.73 (0.53 \u20131.00); p=0.026ctDNA (mutant)Buparlisib + \nFulvestrantPlacebo + \nFulvestrant\nMedian PFS, \nmonths (95% CI)4.2\n(2.8\u20136.7)1.6\n(1.4\u20132.8)\nHR (95% CI) 0.46 (0.29 \u20130.73); p<0.001ctDNA samples \nat study entry \n(BEAMing) \nN=348\nPIK3CA mutant: \n39%Mutant Wild-typeThis presentation is the intellectual property of the author/presenter. Contact them at angelo.dileo@uslcentro.toscana.it for permission to reprint and/or distribute. San Antonio Breast Cancer Symposium \u2013December 6 \u201310, 2016\n47\u2022One confirmed case of Hy\u2019s Law was observed in the buparlisib + fulvestrant arm\n\u2022Three cases of suicidal attempt were reported in the buparlisib + fulvestrant arm vs none in the placebo + fulvestrant armAdverse Events (\u226510% of Patients) Regardless of Relationship to \nStudy Treatment\nALT, alanine aminotransferase; AST, aspartate aminotransferase.Buparlisib + Fulvestrant\nn=288Placebo + Fulvestrant\nn=140\nAdverse event, % All Grades Grade 3/4 All Grades Grade 3/4\nTotal 98 62 91 34\nALT increased 39 22 7 3\nAST increased 37 18 10 3\nHyperglycemia 36 12 3 0\nNausea 34 1 18 2\nDiarrhea 26 3 9 1\nFatigue 23 4 19 1\nDepression 21 1 8 0\nAnxiety 18 1 10 0\nAsthenia 17 2 10 0\nDecreased appetite 16 1 6 1\nDizziness 12 1 7 0\nHypertension 12 6 6 4\nRash 12 2 2 0\nStomatitis 10 1 4 0Fazit Buparlisib -Kombinationstherapien\n\u2022Nebenwirkungen von Buparlisib f\u00fchren \ndazu, dass die Substanz trotz zweier \npositiver Studien nicht weiter verfolgt wird\n\u2022Nebenwirkungen der Pan -PI3KIs im \nVergleich zu CDKIs ung\u00fcnstig\n\u2022Inkonsistente Daten zur pr\u00e4diktiven \nBedeutung der PI3K -Mutation\n\u2022Liquid Biopsy (ctDNA ) wom\u00f6glich besser, \nals Prim\u00e4rtumor?\nDETECT study conceptCTC Biomaterial Program in \ntheDetect -TrialsWhich cells areresponsible\nforprogression ?\nS1 \u2013Damage response\nS2 \u2013EMT and stem cell markers\nS3 \u2013Protein pathway activation\nEpCAM -positive AND \u2013negative CTCsLiquid\nBiopsy\nTumor \nheterogeneity\nResistance\nto therapy\n\uf0a7Hypothesis -driven analysis of \nmolecular targets \n\uf0a7Individualized treatment of \nadvanced breast cancerTranslational research program of DETECT CTC\n-Project aims -\nS5 \u2013Circulating nucleic acids\n(miRNA, ctDNA)\nS4 \u2013Disseminated cancer cells\nin bone marrow\nS6 \u2013Selection of mutations in CTCsWhich biomarker is the best \npredictor for response to therapy ?\nFunded bythe\nGerman Cancer Foundation 1,7 Mio\u20ac\nStrength of DETECT CTC\n-Concerted exploitation of blood samples -\nPI3K andbeyond\n-Landscape endokrine Therapie \nmetastasierter Brustkrebs\n-PI3K -Inhitoren \u2013aktuelle Datenlage\n-PARP -Inhibition\n-Ausblick\nOlympiAD: Phase III trial of olaparib monotherapy versus chemotherapy for patients with HER2 -negative metastatic breast cancer a nd a germline BRCA mutation\nPresented By Mark Robson at 2017 ASCO Annual MeetingOlympiAD study design\nPresented By Mark Robson at 2017 ASCO Annual MeetingPatient characteristics\nPresented By Mark Robson at 2017 ASCO Annual MeetingPrimary endpoint: progression -free survival by BICR\nPresented By Mark Robson at 2017 ASCO Annual MeetingOverall survival (interim analysis; 46% data maturity)\nPresented By Mark Robson at 2017 ASCO Annual MeetingObjective response by BICR\nPresented By Mark Robson at 2017 ASCO Annual MeetingSubgroup analyses: PFS by BICR\nPresented By Mark Robson at 2017 ASCO Annual MeetingTime to deterioration of global HRQoL\nPresented By Mark Robson at 2017 ASCO Annual MeetingSlide 24\nPresented By Mark Robson at 2017 ASCO Annual MeetingPers\u00f6nliches Fazit Olaparib ABC\n\u2022\u00dcberzeugende Daten zu Olaparib nun nach \ndem Ovarial -Caauch beim Mamma -Cabei \ngBRCA -Mutation\n\u2022Zulassung wird sicher kommen\n\u2022F\u00fcr ca. 10% der Patientinnen eine wichtige \nOption\n\u2022Adjuvante Studie in Rekrutierung\nPraxis: umsetzen \u2013abwarten \u2013\nnicht umsetzen\nPI3K andbeyond\n-Landscape endokrine Therapie \nmetastasierter Brustkrebs\n-PI3K -Inhitoren \u2013aktuelle Datenlage\n-PARP -Inhibition\n-Ausblick\nOngoing Clinical Trials of Investigational SERDs in HR +, \nHER2 \u2013ABC\n65Agent Phase Treatment Prior TreatmentTarget \nNPrimary \nEndpoint\nRAD19013,4 1 Monotherapy Progression or\nrecurrence with ET75 MTD\nAZD94962,5 1 Monotherapy Progression or\nrecurrence with ET150 Safety and \ntolerability\nGDC -08106,7 2 FUL vs \nGDC -0810Progression or \nrecurrence on AI152 PFS\n1/2 GDC -0810 + \nPAL \u00b1LHRH \nagonistProgression or \nrecurrence on ET195 RP2D, MTD, \nCBR\nLSZ1028 1 LSZ102 alone; \nLSZ102 + RIBO;\nLSZ102 + BYLProgression or \nrecurrence with ET150 Incidence of \nDLT; safety, \ntolerability \nABC, advanced breast cancer; AI, aromatase inhibitor; ANA, anastrozole; BYL, alpelisib; CBR, clinical benefit rate; DLT, dose -limiting toxicity; ET, endocrine therapy; FUL, fulvestrant; \nHER2 \u2013, human epidermal growth factor receptor -2\u2013negative; HR+, hormone receptor -positive; LHRH, luteinizing hormone -releasing ho rmone; MTD, maximum tolerated dose; OS, overall \nsurvival; ORR; objective response rate; PAL, palbociclib; PFS, progression -free survival; RP2D, recommended phase 2 dose; RIBO, ribociclib; SERD, selective estrogen receptor down -\nregulator/degrader .\n1. Garner F, et al. Anticancer Drugs . 2015;26(9):948 -956; 2. Hamilton, E, et al. SABCS 2016. Abstract P6 -12-03 [poster]; 3. Kakalamani, et al. SABCS 2016. Abstract P2-08-06 [poster]; \n4. NCT02338349; 5. NCT02248090; 6. NCT02569801 ; 7. NCT01823835; 8. NCT02734615 .\uf0a7In clinical practice, \nthe utility of fulvestrant \nis limited by method \nof administration \n(intramuscular \ninjection)1\n\uf0a7Oral SERDs are \ncurrently being \ninvestigated for \npostmenopausal \nwomen with HR+ ABC1,2Immunomodulation in Breast Cancer\n66\nT cell\nDendritic cell\nT cell Tumor\ncellT cell Tumor cellTumor Microenvironment\nActivation\n(cytokines, lysis, \nproliferation,\nmigration to tumor)\nIn breast cancer\n\uf0a7Tumor -infiltrating lymphocytes and PD -L1 expression are associated with better outcome1\n\uf0a7Myeloid -derived suppressor cells are linked to high risk of nodal metastases2Immune checkpoint inhibition \nregimens can result in\n\u2022Late responses and \nunconventional kinetics of \nresponse\n\u2022Long duration of remissions\n\u2022Ability to re -respond to therapy \nafter progression\n\u2022Immune -related AEs\nAE, adverse event; PD -L1, programmed death ligand -1. \n1. Schalper KA, et al. Clin Cancer Res . 2014;20(10):2773 -2782; 2. Yu J, et al. J Immunol . 2013;190(7):3783 -3797.T cellDendritic \ncell\nBlockade\nBlockadeOngoing Clinical Trials of Immune Checkpoint Inhibitors\n(Phase 1/2 in HR+ ABC)\n67Study Phase NEndpoints\nPrimary Secondary\nCohort 2: Pembrolizumab + antiestrogen therapy \n(anastrozole, letrozole, or exemestane ) in HR+, \nHER2\u2212 MBC ( NCT02648477a)2 \u2248 56ORR and\nsafetyCBR, DOR, \nTTF, PFS, OS\nAnti\u2013PD-L1 antibody (durvalumab) + anti \u2013CTLA -4 \nantibody (tremelimumab) in HR+, HER2 \u2013BC\n(NCT03132467)1 \u2248 15Safety, \nfeasibility\u2014\nNeoadjuvant pembrolizumab + decitabine followed by \nstandard neoadjuvant chemotherapy for HER2 \u2013locally\nABC ( NCT02957968)2 \u2248 50Safety, TIL \nlevelspCR, cCR, \nresidual \ndisease, TIL \ninfiltration \nCohort 3: Safety study of nivolumab + nab -paclitaxel \u00b1\ngemcitabine in recurrent MBC ( NCT02309177)1 \u2248 40 SafetyPFS, OS, DCR, \nORR, DoR\nABC, breast cancer; AE, adverse event; CBR, clinical benefit rate; cCR, clinical complete response; DCR, disease control rate ;; DOR, duration of response; HR+, hormone receptor -positive; \nHER2 \u2013, human epidermal growth factor receptor -2\u2013negative; MBC, metastatic breast cancer; ORR, overall response rate; OS, overall survival; pCR, pathological complete response; \nPD-1, programmed death -1; PFS, progression -free survival; PK, pharmacokinetics;; TIL, tumor infiltrating lymphocyte; TTF, time t o treatment failure.\na This is a combined trial in TNBC and HR+ HER2 \u2013BC, with 2 cohorts.\nAvailable from clinicaltrials.gov.Fazit: PI3K -Inhibitoren andbeyond \u2026\n-PI3K -Inhibitoren beim HR -posmetastasierten Brustkrebs wirksam \n\u2013sowohl prim\u00e4r, als auch in der endokrinen Therapieresistenz\n-Pan-PI3K -Inhibitoren wegen hoher Toxizit\u00e4t vermutlich nicht \npraxistauglich\n-Datenlage zur Rolle der PI3K -Mutation unklar \u2013liquid biopsy\nwom\u00f6glich besser\n-Beyond ist jetzt: Olaparib beim BRCA -ass. Met. Brustkrebs \neinsetzbar\n-Further beyond : we\u2018ll see\u2026..\n", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}